EGFR and neoplasm: Randomised trials had previously shown increased tumour response rates and progression-free survival with EGFR-TKI treatment in EGFR gene mutation-positive patients [2–8], and with platinum-doublet combination chemotherapy in EGFR gene mutation-negative patients [9, 10], who had previously untreated metastatic non-squamous NSCLC.